Commercial Liquid Biopsy for Early Detection: Ethical Realities & Specificity Defects Report: Guardian Australia Analysis on Commercial Liquid Biopsies | Access Full Report via The Guardian The Bottom Line Direct-to-consumer advertising is currently marketing a $1,495 out-of-pocket liquid biopsy test (circulating tumour DNA) to Australian women for asymptomatic ovarian cancer. While early detection remains a critical goal, health leaders—including the Ovarian Cancer Research Foundation (OCRF)—warn that commercially offering this unapproved TGA test carries major ethical concerns and severe diagnostic limitations. With a sensitivity of ~78% and a specificity of ~94%, the test simultaneously misses a quarter of true cancers while generating thousands of false alarms in healthy women. The Two-Way Diagnostic Flaw ┌─────────────────────────────────────────────────────────────────────────┐ │ COMMERCIAL TEST PROFILE │ ├────────────────────...

Predicting Long-Term Survival in Advanced Ovarian Cancer Study: Retrospective survey of 359 women with advanced ovarian cancer. | Access Full Study via ScienceDirect The Bottom Line Long-term survival is an achievable reality for a significant subset of patients with advanced ovarian cancer. Approximately 30% of women in this group achieved long-term survival reaching the 10-year mark . Key positive survival drivers include complete surgical resection at primary cytoreduction, the presence of a BRCA mutation, and a high baseline level of general well-being and independence. Conversely, clear cell histology continues to mean poor long-term survival outcomes. Key Predictors of 10-Year Survival The survey identifies four distinct clinical and biological markers that shape the long-term horizon: Surgical Outcomes: Complete macroscopic removal of the cancer during the primary surgical procedure remains the single most impactful clinical factor for survival. The BRCA Paradox: While a BRC...

Emergency Room Ovarian Cancer Diagnoses Study: Population-based cohort of 28,204 women (England, 2017–2021). Access Full Study The Bottom Line An astonishing 40% (2 in 5) of ovarian cancer patients are diagnosed within 28 days of an emergency room admission. This represents a systemic failure that almost always results in late-stage diagnoses and poor survival rates. Who is Missing the Diagnostic Window? The data show emergency presentations aren't random; they split into two clear, vulnerable groups: The Disadvantaged Young: Younger women from low socioeconomic backgrounds facing barriers to primary medical care. The Frail Elderly: Older women with complex, competing comorbidities that mask vague cancer symptoms. The Pandemic Spike: Emergency diagnoses peaked sharply in 2020 , proving that when routine primary care access shrinks, emergency cancer presentations surge. What OCA Support Nurses Need to Know High-Distress Intake: ER-diagnosed patients skip the gradual preparatio...

Oophorectomy-Corrected Ovarian Cancer Incidence, Survival, and Mortality by Subtype, Race, Ethnicity https://tinyurl.com/tk4v75pj Ovarian cancer is declining. This decrease is mostly attributed to hormonal contraception, which means fewer lifetime menstrual cycles. This effect has been noted for the almost 60 years that hormonal contraception has been available and has increased with time as the users aged. As other forms of contraception develop, oral hormonal contraception is now used by 11% of the US population. Despite this, the incidence of ovarian cancer continues to fall ; the reasons are not clear. One suggestion is that removal of ovaries (oophorectomy) for reasons other than cancer may have the effect of reducing ovarian cancer. This study looked at the SEER cancer registry . A lmost 160000 cases of ovarian cancer were recorded during the period 2002 -2019. The rate of ovarian cancer decreased by about 2% for white women and less , about 1. 5 % for black women. The ra...

Long-Term Outcomes in Patients w ith Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors https://tinyurl.com/y937k685 When PARP inhibitor therapy was first introduced, it was supposed to be maintenance t reatment aimed at slowing the progression of ovarian cancer. The measure of success was hel d to be progression-free s urvival ; cure was not expected with most, if not all, patients with ovarian cancer dying from the disease. It soon became clear that there was a subgroup of patients whose survival was prolonged beyond the 5-year “ cure ” marker . This was noted in all the clinical trials with up to 20% of participants in the SOLO 2 still alive 5 years later. This retrospective study was of 320 patients who were part of this group , with a history of exceptional survival . About two-thirds of them had received continual treatment with PARP inhibitors ; the others had discontinued the drug either due to carer intervention or due to adverse effects or pers...